Asterias Biotherapeutics, Inc. , a leading biotechnology company in the emerging field of regenerative medicine, today reported financial results and progress for the quarter and year ended December 31, 2014, as well as, recent corporate developments. "Asterias has two therapeutic programs with proof-of-concept in our portfolio that have the potential to address significant unmet medical needs using our pluripotent stem cell technology platform, and we achieved substantial progress with these programs during this past year," stated Pedro Lichtinger, President and CEO of Asterias.
http://ift.tt/1MpKG59
http://ift.tt/1MpKG59
No comments:
Post a Comment